Federal Register / Vol. 75, No. 202 / Wednesday, October 20, 2010 / Notices 64745 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of Cocaine (9041), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture a 

radioactive product used in diagnostic 

imaging in the diagnosis of Parkinson’s 

Disease and for manufacture in bulk for 

investigational new drug (IND) 

submission and clinical trials. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such a substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26443 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 12, 2010, 

Noramco Inc., 500 Swedes Landing 

Road, Wilmington, Delaware 19801– 

4417, made application by renewal to 

the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedules I and II: 

Drug Schedule 

Codeine-N-oxide (9053) ............... I 

Dihydromorphine (9145) ............... I 

Morphine-N-oxide (9307) ............. I 

Methylphenidate (1724) ................ II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Opium extracts (9610) .................. II 

Opium fluid extract (9620) ............ II 

Opium tincture (9630) .................. II 

Opium, powdered (9639) ............. II 

Opium, granulated (9640) ............ II 

Oxymorphone (9652) ................... II 

Drug Schedule 

Noroxymorphone (9668) .............. II 

Tapentadol (9780) ........................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administrator, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26456 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 7, 2010, 

National Center for Natural Products 

Research—NIDA MProject, University of 

Mississippi, 135 Coy Waller Lab 

Complex, University, Mississippi 38677, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

I: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to cultivate 

marihuana for the National Institute on 

Drug Abuse for research approved by 

the Department of Health and Human 

Services. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26450 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on August 20, 2010, 

Halo Pharmaceutical Inc., 30 North 

Jefferson Road, Whippany, New Jersey 

07981, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Hydromorphone (9150) ................ II 

Dihydromorphine is an intermediate 

in the manufacture of Hydromorphone 

and is not for commercial distribution. 

The company plans to manufacture 

Hydromorphone HCL for sale to other 

manufacturers and for the manufacture 

of other controlled substance dosage 

units for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 20, 2010. 

Dated: October 8, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–26469 Filed 10–19–10; 8:45 am] 

BILLING CODE 4410–09–P 


emcdonald on DSK2BSOYB1PROD with NOTICES